MRI use before prostate biopsies surges across U.S. hospitals

Across American hospitals, a quiet shift is underway in how doctors approach one of the most common cancer diagnoses. Before inserting a needle into a man's prostate to collect tissue samples, more clinicians are now ordering an MRI first—a practice that has surged in adoption over recent years and is reshaping the standard pathway for prostate cancer detection.

The change reflects a growing body of evidence suggesting that magnetic resonance imaging, which produces detailed cross-sectional pictures of the prostate, meaningfully improves the odds that a biopsy will find cancer if it exists and avoid unnecessary sampling if it does not. Where MRI before biopsy was once considered optional or experimental at many institutions, it has become routine at a widening number of hospitals nationwide. The shift is not driven by marketing or habit, but by data showing that the quality of the MRI directly influences whether the subsequent biopsy succeeds in its diagnostic mission.

Prostate biopsies carry real stakes. The procedure involves inserting a needle through the rectal wall to extract tissue cores from the prostate gland, a walnut-sized organ that sits beneath the bladder. It carries risks of infection, bleeding, and urinary retention. Men undergoing biopsy are often anxious about the result—whether cancer will be found, whether the sampling will be thorough enough, whether they will need treatment. A biopsy that misses existing cancer or that proves unnecessary because imaging could have ruled out disease represents both a clinical failure and a source of patient harm.

MRI addresses this problem by allowing radiologists to visualize the prostate in high resolution before the needle goes in. Suspicious areas—regions that appear abnormal in size, shape, or signal intensity—can be identified and marked. When the urologist performs the biopsy, he or she can target those specific zones rather than sampling the gland blindly or according to a generic template. The result is a higher likelihood of detecting cancer that is present and a lower likelihood of performing biopsies on men who do not have disease.

The adoption of this practice across U.S. hospitals signals a maturation of prostate cancer diagnosis. For decades, the standard approach relied on a blood test called PSA (prostate-specific antigen) followed by a biopsy if the PSA was elevated. But PSA is imperfect—it rises in cancer but also in benign conditions like infection or enlargement. Many men with elevated PSA do not have cancer, yet they underwent biopsy anyway. MRI offers a middle ground: it can help distinguish which elevated PSA readings warrant biopsy and which do not, reducing unnecessary procedures while improving the detection of clinically significant disease.

Hospitals and health systems have taken notice. The surge in MRI-before-biopsy protocols reflects both the accumulating clinical evidence and the practical reality that patients and their doctors increasingly expect imaging before invasive procedures. Some institutions have made it a formal requirement; others have adopted it as a strong recommendation. The trend is visible in radiology departments, where demand for prostate MRI has grown, and in urology clinics, where the workflow now routinely includes imaging review before scheduling a biopsy.

What remains to be seen is whether this shift will extend further into the screening phase—whether MRI might eventually replace or supplement PSA testing as the first-line tool for identifying men at risk. For now, the change is focused on the biopsy decision: once a man's PSA is elevated or his digital rectal exam is abnormal, MRI has become the logical next step. As more hospitals adopt the practice and more data accumulate, the question is not whether MRI improves biopsy outcomes—the evidence already suggests it does—but how quickly the entire system will align around this new standard and what it will mean for the millions of American men facing prostate cancer risk.